UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     
Date of Report (Date of Earliest Event Reported):   May 5, 2015

Charles River Laboratories International, Inc.
__________________________________________
(Exact name of registrant as specified in its charter)

     
Delaware 001-15943 06-1397316
_____________________
(State or other jurisdiction
_____________
(Commission
______________
(I.R.S. Employer
of incorporation) File Number) Identification No.)
      
251 Ballardvale St., Wilmington, Massachusetts   01887
_________________________________
(Address of principal executive offices)
  ___________
(Zip Code)
     
Registrant’s telephone number, including area code:   781-222-6000

Not Applicable
______________________________________________
Former name or former address, if changed since last report

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[  ]  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[  ]  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[  ]  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[  ]  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Item 5.07. Submission of Matters to a Vote of Security Holders

Charles River Laboratories International, Inc. (Company) held its Annual Meeting of Shareholders on May 5, 2015. For more information on the following proposals, see the Company’s proxy statement dated March 31, 2015. At the Company’s Annual Meeting, the following proposals were adopted by the votes specified below:

(a) The following nine (9) directors were elected to serve until our 2016 Annual Meeting of Shareholders and received the number of votes listed opposite each of their names below:

                                 
    Number of Shares   Number of Shares   Number of Shares   Broker Non-Votes
    Voted For   Voted Against   Abstained        
James C. Foster
    40,725,478       1,134,168       108,814       1,539,304  
Robert J. Bertolini
    41,700,304       154,159       113,997       1,539,304  
Stephen D. Chubb
    41,208,192       646,827       113,441       1,539,304  
Deborah T. Kochevar
    37,168,165       4,686,959       113,336       1,539,304  
George E. Massaro
    41,450,244       404,169       114,047       1,539,304  
George M. Milne, Jr.
    41,013,488       720,087       234,885       1,539,304  
C. Richard Reese
    41,710,440       146,099       111,921       1,539,304  
Craig B. Thompson
    41,676,015       180,274       112,171       1,539,304  
Richard F. Wallman
    38,002,202       3,729,897       236,361       1,539,304  

(b) The shareholders approved, on an advisory, non-binding basis, the compensation of our named executive officers.

                         
For
  Against   Abstain   Broker Non-Votes
41,012,917
    771,262       184,281       1,539,304  

(d) The shareholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as our independent auditors for fiscal 2015.

                         
For
  Against   Abstain   Broker Non-Votes
42,492,232
    906,725       108,807       0  

Computershare Trust Company, N.A., our transfer agent, acted as independent proxy tabulator and Inspector of Election at the Annual Meeting of Shareholders.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

         
    Charles River Laboratories International, Inc.
          
May 11, 2015   By:   Matthew Daniel
       
        Name: Matthew Daniel
        Title: Corporate Vice President, Legal Compliance & Deputy General Counsel